Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Janssen joins a long list of big pharma partners betting on PeptiDream's macrocyclic peptide discovery platform, with $1.15B in milestone potential reflecting…
The deal continues PeptiDream's pattern of stacked discovery collaborations with global pharma; success ultimately depends on whether any program advances to…
PeptiDream shares jumped 19% on the Janssen deal announcement as investors viewed the latest big-pharma alliance as further validation of platform durability.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
PeptiDream entered a multi-target peptide discovery collaboration with Janssen worth up to $1.15B in preclinical, clinical and commercialization milestones plus undisclosed royalties. Janssen received development and commercialization rights plus an option to peptide-drug conjugate (PDC) applications. Targets cover metabolic and cardiovascular indications. Upfront and research funding undisclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc. (Johnson & Johnson) / PeptiDream Inc. (this deal) | 2017 | $1.1B | — |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2017 deals · Cardiovascular deals